To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of a streamlined data review program.

Bill: 114-hr-2415
Sponsor: full_name: Rep. Burgess, Michael C. [R-TX-26]
Introduced: 2015-05-19
Policy area: Health
Subjects: Drug safety, medical device, and laboratory regulation

Government information and archives

Health information and medical records

Licensing and registrations
Latest action: action_date: 2015-05-22
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2015-05-19
action_desc: Introduced in House
text: <p>This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a streamlined data review program under which the holder of an approved application for a drug or biological product may submit a summary of clinical data to support approval of the drug for the treatment of cancer or another indication subject to the program.</p> <p>For a drug to be eligible for the streamlined data review program there must be a database regarding the safety of the drug and the full data sets used to develop the data summaries must be submitted, unless the FDA determines that the full data sets are not required.</p> The FDA must annually publish: (1) the number of applications reviewed under the streamlined data review program, (2) the average time for completion of review under the streamlined data review program compared to review of other applications for new indications, and (3) the number of applications reviewed under the streamlined data review program for which the FDA made use of full data sets.

tv_txt: I 114th CONGRESS 1st Session H. R. 2415 IN THE HOUSE OF REPRESENTATIVES May 19, 2015 Mr. Burgess (for himself and Mr. Engel ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of a streamlined data review program.

1. Streamlined data review program (a) In general Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 505F of such Act ( 21 U.S.C. 355f ) the following: 505F. Streamlined data review program (a) In general The Secretary shall establish a streamlined data review program under which a holder of an approved application submitted under section 505(b)(1) or under section 351(a) of the Public Health Service Act may, to support the approval or licensure (as applicable) of the use of the drug that is the subject of such approved application for a new qualified indication, submit qualified data summaries. (b) Eligibility In carrying out the streamlined data review program under subsection (a), the Secretary may authorize the holder of the approved application to include one or more qualified data summaries described in subsection (a) in a supplemental application if— (1) the drug has been approved under section 505(c) of this Act or licensed under section 351(a) of the Public Health Service Act for one or more indications, and such approval or licensure remains in effect; (2) the supplemental application is for approval or licensure (as applicable) under such section 505(c) or 351(a) of the use of the drug for a new qualified indication under such section 505(c) or 351(a); (3) there is an existing database acceptable to the Secretary regarding the safety of the drug developed for one or more indications of the drug approved under such section 505(c) or licensed under such section 351(a); (4) the supplemental application incorporates or supplements the data submitted in the application for approval or licensure referred to in paragraph (1); and (5) the full data sets used to develop the qualified data summaries are submitted, unless the Secretary determines that the full data sets are not required. (c) Public availability of information on program The Secretary shall post on the public website of the Food and Drug Administration and update annually— (1) the number of applications reviewed under the streamlined data review program; (2) the average time for completion of review under the streamlined data review program versus other review of applications for new indications; and (3) the number of applications reviewed under the streamlined data review program for which the Food and Drug Administration made use of full data sets in addition to the qualified data summary. (d) Definitions In this section: (1) The term qualified indication means— (A) an indication for the treatment of cancer, as determined appropriate by the Secretary; or (B) such other types of indications as the Secretary determines to be subject to the streamlined data review program under this section. (2) The term qualified data summary means a summary of clinical data intended to demonstrate safety and effectiveness with respect to a qualified indication for use of a drug. . (b) Sense of Congress It is the sense of Congress that the streamlined data review program under section 505F of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), should enable the Food and Drug Administration to make approval decisions for certain supplemental applications based on qualified data summaries (as defined in such section 505F). (c) Guidance; regulations The Commissioner of Food and Drugs— (1) shall— (A) issue final guidance for implementation of the streamlined data review program established under section 505F of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), not later than 24 months after the date of enactment of this Act; and (B) include in such guidance the process for expanding the types of indications to be subject to the streamlined data review program, as authorized by section 505F(c)(1)(B) of such Act; and (2) in addition to issuing guidance under paragraph (1), may issue such regulations as may be necessary for implementation of the program.